ductal carcinoma in situ
Their study showed that DCIS patients with pathogenic variants in BRCA1/2 and PALB2 had a higher risk of developing invasive breast cancer than those without.
Oncologists said the five-year outcomes data aren't enough to change standard of care but could inform conversations between patients and their doctors.
Researchers ID Genomic Signature to Risk Stratify Patients With Precancerous Breast Lesions
In the study, presented at SABCS, researchers developed an 812-gene signature that could identify which patients with ductal carcinoma in situ need aggressive treatment.
For patients with ductal carcinoma in situ, stromal PDGFRb expression could predict radiation benefit, and potentially lead to effective combination therapies.
PreludeDx DCIS Breast Cancer Test Helps Determine Radiation Therapy Benefits, Reduce Overtreatment
Premium
The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.